-2 -Prevalence of extended-spectrum β-lactamases (ESBLs) has limited the available 1 therapeutic options and necessitated the increased use of carbapenems against Klebsiella 2 pneumoniae infections. In response to use of carbapenems, carbapenem resistance has 3 developed and flourished. In 1996, a new β-lactamase termed "K. pneumoniae 4 carbapenemase" (KPC) was reported in New York City (12). Subsequently, producing K. pneumoniae has been spread worldwide (9). However, it has not hitherto 6 been reported in South Korea. We report a case of infection with KPC-producing 7 extreme-drug resistant (XDR) K. pneumoniae isolate in a tertiary care hospital in South 8 Korea.
9
A 65-year-old male patient who had diabetic mellitus and chronic renal failure on showed whitish dirty mucous membrane, compatible with pseudomembranous colitis.
4
The patient was admitted to the intensive care unit under the diagnosis of sepsis due to performed uneventfully. Post-operatively, the patient displayed purulent sputum, and bla SHV-11 were also evident. In addition, bla KPC-2 was also present, which is the first 1 4 detection in South Korea.
5
To investigate the genotype of Kpn-DK2, multilocus sequence typing (MLST) was 1 6
performed, as described previously (4) reported, to our knowledge, ST258 and ST11 are single locus variants of each other that 2 0 differ in the tonB allele, and both are widespread clonal groups. Notably, ST11 is the 2 1 most common clone of ESBL-producing K. pneumoniae isolates in Korea (unpublished).
2
Despite lack of evidence of the spread of KPC-producing isolates, it is worrisome that a 2 3
KPC-producing K. pneumoniae isolate has been found in a common ESBL-producing Pseudomonas aeruginosa isolates from a cystic fibrosis patient. Int. J. Antimicrob.
7
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